Brokerages Expect Five Prime Therapeutics Inc (NASDAQ:FPRX) Will Announce Quarterly Sales of $5.53 Million

Analysts forecast that Five Prime Therapeutics Inc (NASDAQ:FPRX) will announce sales of $5.53 million for the current quarter, Zacks reports. Five analysts have provided estimates for Five Prime Therapeutics’ earnings. The highest sales estimate is $7.60 million and the lowest is $2.00 million. Five Prime Therapeutics reported sales of $7.58 million during the same quarter last year, which would suggest a negative year over year growth rate of 27%. The firm is expected to report its next earnings results on Wednesday, August 14th.

On average, analysts expect that Five Prime Therapeutics will report full year sales of $19.99 million for the current fiscal year, with estimates ranging from $5.30 million to $30.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $60.28 million, with estimates ranging from $30.00 million to $139.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.05. The company had revenue of $5.35 million during the quarter, compared to analyst estimates of $5.71 million. Five Prime Therapeutics had a negative net margin of 683.89% and a negative return on equity of 54.87%.

FPRX has been the subject of several analyst reports. ValuEngine raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 20th. Guggenheim initiated coverage on shares of Five Prime Therapeutics in a research report on Friday, April 12th. They set a “buy” rating and a $24.00 price target for the company. Cowen reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Wednesday, February 27th. Roth Capital initiated coverage on shares of Five Prime Therapeutics in a research report on Wednesday, May 29th. They set a “neutral” rating and a $10.00 price target for the company. Finally, BidaskClub lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. Five Prime Therapeutics presently has an average rating of “Hold” and an average target price of $20.00.

Several hedge funds have recently added to or reduced their stakes in the business. Franklin Street Advisors Inc. NC grew its stake in shares of Five Prime Therapeutics by 200.0% in the first quarter. Franklin Street Advisors Inc. NC now owns 30,000 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 20,000 shares in the last quarter. Granite Investment Partners LLC grew its stake in shares of Five Prime Therapeutics by 87.8% in the first quarter. Granite Investment Partners LLC now owns 32,442 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 15,164 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Five Prime Therapeutics during the 1st quarter valued at approximately $160,000. DekaBank Deutsche Girozentrale grew its stake in Five Prime Therapeutics by 2,393.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 284,200 shares of the biotechnology company’s stock valued at $4,019,000 after purchasing an additional 272,800 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Five Prime Therapeutics during the 1st quarter valued at approximately $1,158,000. 86.94% of the stock is owned by institutional investors and hedge funds.

Shares of FPRX stock traded down $0.48 during mid-day trading on Friday, hitting $5.90. 910,190 shares of the stock traded hands, compared to its average volume of 464,018. The firm has a market cap of $212.78 million, a price-to-earnings ratio of -1.43 and a beta of 3.10. Five Prime Therapeutics has a 52-week low of $5.80 and a 52-week high of $17.88. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.41 and a current ratio of 10.41.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Recommended Story: What are no-load funds?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.